Lexapro (escitalopram oxalate) tablets and oral solution
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
Monoamine Oxidase Inhibitors (MAOIs)
- The use of MAOIs intended to treat psychiatric disorders with Lexapro or within 14 days of stopping treatment with Lexapro is contraindicated because of an increased risk of serotonin syndrome. The use of Lexapro within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated…
WARNINGS AND PRECAUTIONS
- The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including Lexapro, alone but particularly with concomitant use of other serotonergic drugs (including Triptans, Tricyclic antidepressants, Fentanyl, Lithium, Tramadol, Tryptophan, Buspirone, and St. John’s Wort) and with drugs that impair metabolism of Serotonin (in particular,MAOIs, both those intended to treat psychiatric disorders and also others, such as Linezolid and intravenous methylene blue).
- new QTc language